Navigation Links
Public session of the Cancer Drug Development Roundtable at Ohio State
Date:4/25/2011

The Ohio State University Comprehensive Cancer CenterArthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC-James) and Friends of Cancer Research (Friends) are convening a high-level group of stakeholders to discuss current obstacles halting co-development of two or more experimental drugs for the treatment of cancer.

In December 2010, the U.S. Food and Drug Administration (FDA) released a Guidance Document addressing the protocol researchers should follow when deciding if co-developing drugs is appropriate. However, barriers found outside of clinics and labs, such as business, legal, liability and intellectual property issues were not examined in detail.

The objective of the Cancer Drug Development Roundtable is to develop a set of recommendations for the FDA to be revealed later this year, addressing industry hurdles currently halting co-development, with the ultimate goal of easing the process and bringing revolutionary cancer treatments to patients faster and with more efficiency.

Prior to the closed working session occurring later in the day, Roundtable participants will hold an open public session for researchers, advocates, patients and media that would like to learn more about the issue and ask questions. Panel participants include:

  • Michael Caligiuri, M.D. - Director of The Ohio State Comprehensive Cancer Center and CEO of the James Cancer Hospital and Solove Research Institute
  • Jim Doroshow, M.D. - Director of the Division of Cancer Treatment and Diagnosis at the National Cancer Institute
  • Eric Rubin, M.D. - Vice President, Oncology Clinical Research, Merck
  • Ellen Sigal, Ph.D. - Chair and Founder, Friends of Cancer Research
  • Janet Woodcock, M.D. - Director, Center for Drug Evaluation and Research, FDA

WHERE: The Ohio State University, Biomedical Research Tower, Room 115, 460 W. 12th Avenue, Columbus, OH 43210

For those unable to attend in person, the Public Session will also be made available via Webcast and teleconference (Please RSVP to lbryan@spectrumscience.com for dial-in information and link).

WHEN: Wednesday, May 4, 2011
10:00 11:00 a.m.

WHO: Hosted by Ohio State University Comprehensive Cancer CenterArthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC-James) and Friends of Cancer Research (Friends)


'/>"/>

Contact: Eileen Scahill
Eileen.Scahill@osumc.edu
614-293-3737
Ohio State University Medical Center
Source:Eurekalert

Related medicine news :

1. The private sale of drugs in public hospitals
2. Governor Rendell Proposes Budget With No Tax Increase, More Money for Public Schools, Strategy for Jobs, Plan to Address Future Deficits
3. Republicans Give Top Award to Betsy McCaughey, Healthcare Patriot, & Rev Up for Upcoming Elections
4. Global Health Defined as Public Health in a New Lancet Commentary by the Association of Schools of Public Health (ASPH)
5. Labopharm announces pricing of US$20 million public offering of units
6. 5W Public Relations Adds Halo/Air Salt Rooms to Its Health & Wellness Client Roster
7. Trade Privacy LLC: Research Concludes Apple Inc. Has Blocked Their Import Records from Public Access
8. BCS Global Launches PSVN (Public Switched Video Network), an Initiative to Provide a Framework for Inter-Connecting Business to Business Video Networks
9. Labopharm announces closing of US$20 million public offering of units
10. Registered Nurses from Public Health - Seattle & King County Hold Informational Picket to Highlight Public Safety Concerns
11. AADR awards the 2010 Jack Hein Public Service Award to David C. Johnsen
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... (PRWEB) , ... January 20, 2017 , ... Doctor C ... it attended the January ECRM trade show to continue the marketing and distribution of ... C supplement, known for providing 400 percent better absorption than traditional vitamin C supplements. ...
(Date:1/20/2017)... ... January 20, 2017 , ... International Protein, a company based out of ... it attended the January ECRM trade show in Hilton Head, SC. , International ... determined to create a line of products that would elevate her fitness regime. At ...
(Date:1/20/2017)... ... ... “Mary Magdalene: Grace is Greater than Sin”: a unique and memorable piece of ... Magdalene: Grace is Greater than Sin” is the creation of published author, Brenda Roberts, ... who had little knowledge of the female characters portrayed in the Holy Bible. ...
(Date:1/20/2017)... Farmville, NC (PRWEB) , ... January 20, 2017 ... ... the vPEP ® Oscillating Positive Expiratory Pressure (OPEP) device, was featured in ... article by Doug Pursley, MEd, RRT-ACCS, FAARC, “Analysis of Three Oscillating Positive ...
(Date:1/20/2017)... ... ... “The Land of More and More”: a brilliant story for children ... the simple and achievable answer. “The Land of More and More” is the creation ... in Angola, Indiana where he works with the children’s ministry department. , Michael ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... 19, 2017 Incretin Mimetics/GLP-1 Agonists, SNDRIs, Lipase ... The global anti-obesity drugs market is expected to ... the forecast period and CAGR of 38.7% in the second half ... a CAGR of 32.8% from 2016 to 2027. The market is ... $24,063 million in 2027. ...
(Date:1/19/2017)... -- Accuray Incorporated (Nasdaq: ARAY ) announced ... set the bar for excellence in customer satisfaction. The ... rating among radiation treatment delivery systems in the U.S., ... Briefing™. The most recent ratings trend also shows Accuray ... for 11 of the past 12 quarters. ...
(Date:1/19/2017)... LONDON , January 19, 2017 ... Grothey ; European Oncology & Haematology, 2016;12(Suppl 2):3-8; ... ... http://photos.prnewswire.com/prnh/20151014/276718LOGO) Published recently in ... the peer-reviewed journal from touchONCOLOGY, an article by ...
Breaking Medicine Technology: